News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Auris Medical AG Announces Enrollment Of First Patient In North American Phase 3 Study Of AM-101 In Treatment Of Acute Peripheral Tinnitus



3/10/2014 9:12:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASEL, Switzerland, March 10, 2014 (GLOBE NEWSWIRE) -- Auris Medical today announced enrollment of the first patient into the TACTT21 clinical trial. This phase 3 trial will evaluate the efficacy, safety and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media. TACTT2 will enroll 330 patients at more than 60 sites primarily in the United States and Canada.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES